Related references
Note: Only part of the references are listed.Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
John Araujo et al.
CANCER TREATMENT REVIEWS (2010)
Mutation-driven drug development in melanoma
Keith T. Flaherty et al.
CURRENT OPINION IN ONCOLOGY (2010)
KIT as a Therapeutic Target in Melanoma
Maria C. Garrido et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
G. E. Konecny et al.
BRITISH JOURNAL OF CANCER (2009)
Combination Targeted Therapy in Advanced Renal Cell Carcinoma
Jeffrey Sosman et al.
CANCER (2009)
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Chemotherapy and biologic therapies for melanoma: do they work?
Lucia B. Jilaveanu et al.
CLINICS IN DERMATOLOGY (2009)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Scott E. Woodman et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma
Jade Homsi et al.
MELANOMA RESEARCH (2009)
Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials
Jiri Pavlu et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Major response to imatinib mesylate in KIT-mutated melanoma
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Alex J. Eustace et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
Ralf Buettner et al.
MOLECULAR CANCER RESEARCH (2008)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
Fei Huang et al.
CANCER RESEARCH (2007)
2-aminothiazole as a novel kinase inhibitor template.: Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor
Jagabandhu Das et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Beyond imatinib: Second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors
Margaret von Mehren
CLINICAL COLORECTAL CANCER (2006)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases
Alireza Mirmohammadsadegh et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis
W Bin Fang et al.
ONCOGENE (2005)
Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate
M Furuhashi et al.
CANCER RESEARCH (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
G Niu et al.
ONCOGENE (2002)
CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size
SA Sohaib et al.
BRITISH JOURNAL OF RADIOLOGY (2000)